Track Abeona Therapeutics Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Abeona Therapeutics Inc. ABEO · Stock Open Abeona Therapeutics Inc. in new tab

4.22 USD
P/E
7.60
EPS
-1.18
P/B
1.94
ROE
-43.13
Beta
1.30
Target Price
18.88 USD
Loading chart...
Key Metrics
Earnings dateNov. 11, 2026
P/E7.60
EPS-1.18
Book Value2.24
Price to Book1.94
Debt/Equity15.52
% Insiders12.290%
Growth
Revenue Growth27.45%
Earnings Growth13.70%
Estimates
Forward P/E-20.96
Forward EPS-0.21
Target Mean Price18.88

DCF valuation

Model fair value for Abeona Therapeutics Inc. (ABEO)
Result
Sign in to run the valuation for ABEO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus None · mean target 18.88 USD (low 14.00, high 30.00) · as of 31 Oct 2026
Low 14.00
Mean 18.88
High 30.00
Price 4.22
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Abeona Therapeutics Inc. Logo Abeona Therapeutics Inc. Analysis (ABEO)

United States Health Care Official Website Stock

Is Abeona Therapeutics Inc. a good investment? Abeona Therapeutics Inc. (ABEO) is currently trading at 4.22 USD. Market analysts have a consensus price target of 18.88 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 7.60. This relatively low multiple may signal that Abeona Therapeutics Inc. is undervalued compared to historical market norms.

Earnings Schedule: Abeona Therapeutics Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.21.

Investor FAQ

Does Abeona Therapeutics Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Abeona Therapeutics Inc.?

Abeona Therapeutics Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -1.18.

Company Profile

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Exchange Ticker
LSE (United Kingdom) 0H7R.L
NCM (Australia) ABEO
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2000
3,706.84 USD
March 31, 2000 0.5930
March 31, 2000 3,706.2500
Stock Splits
Split Date Split Ratio to 1
April 16, 1992 1:2
June 5, 1998 1
June 18, 1998 1:20
June 5, 2006 1:5
Oct. 24, 2014 1:50
July 5, 2022 1:25
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion